Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

Introduction

Pemitinib is identified on this website as a product containing pemigatinib in a stated strength of 13.5 mg.

Understanding the organization responsible for a pharmaceutical product is important for patients, healthcare professionals and pharmaceutical supply organizations.

However, the manufacturer of a specific branded medicine should never be identified through assumptions based only on its active ingredient or similarity to another product.

The manufacturer of the specific Pemitinib product has not been independently established in the information available for this website. Its identity should be confirmed through the actual product packaging and official pharmaceutical documentation.

This page explains the pharmaceutical background of pemigatinib and the difference between its reference product, developer, manufacturer and authorization holder.

Understanding Pemigatinib

Pemigatinib is a targeted anticancer medicine belonging to the fibroblast growth factor receptor inhibitor class.

It selectively inhibits FGFR1, FGFR2 and FGFR3.

These receptors participate in cellular signaling processes that influence cell growth, survival and other biological functions.

Certain cancers develop genetic abnormalities involving FGFR pathways. These abnormalities may contribute to abnormal signaling and cancer progression.

Pemigatinib is designed to inhibit the activity of these receptors in selected patients whose tumors or blood cancers have qualifying molecular abnormalities.

Its clinical use depends on the applicable indication, molecular testing requirements and local prescribing information.

The Reference Product: PEMAZYRE

PEMAZYRE is the established reference brand containing pemigatinib.

The reference product provides important information about the active ingredient, recognized clinical uses, dosage schedules, pharmaceutical formulation and safety considerations.

The reference product is available in 4.5 mg, 9 mg and 13.5 mg tablet strengths.

The 13.5 mg strength is therefore an established pemigatinib tablet strength.

However, the existence of a reference product does not establish the manufacturer or regulatory status of every other product that may contain pemigatinib.

Incyte and Pemigatinib Development

Incyte is associated with the development of pemigatinib and the reference product PEMAZYRE.

The company’s role in the development of pemigatinib provides important background about the active pharmaceutical ingredient and the scientific development of the reference medicine.

However, the role of a development company should not automatically be confused with the manufacturing identity of another branded product.

The specific manufacturer of Pemitinib must be confirmed independently.

Who Manufactures Pemitinib?

The specific manufacturer of Pemitinib 13.5 mg requires confirmation from product-specific documentation.

The company responsible for producing a particular medicine should be identified through appropriate evidence, such as:

  • Product packaging.
  • Official package leaflet.
  • Manufacturer’s declaration.
  • Pharmaceutical quality documentation.
  • Regulatory registration records.
  • Marketing authorization documentation.

Without this evidence, naming a particular company as the manufacturer would be misleading.

Manufacturer, Developer and Brand Owner: What Is the Difference?

Pharmaceutical products may involve several organizations with different responsibilities.

Drug developer

The developer is associated with discovering or developing the active pharmaceutical ingredient or original medicine.

Product manufacturer

The manufacturer is responsible for producing the specific medicine under applicable pharmaceutical quality requirements.

Brand owner

The brand owner controls or owns the commercial product name.

Marketing authorization holder

The marketing authorization holder is the legal organization responsible for the product’s authorization in a particular regulatory jurisdiction.

Distributor

The distributor participates in the authorized supply and distribution of the product.

Supplier

The supplier provides the medicine through a particular commercial, institutional or pharmaceutical supply channel.

These roles can belong to different organizations. They should be described accurately rather than treated as interchangeable.

Why Manufacturer Verification Matters

Manufacturer information is an important part of medicine identification.

It helps healthcare professionals and pharmaceutical organizations establish where a product comes from and which organization is responsible for its production.

It can also help support:

  • Product traceability.
  • Batch identification.
  • Quality documentation.
  • Recall communication.
  • Product complaints.
  • Adverse-event reporting.
  • Regulatory compliance.
  • Supply-chain assessment.

For prescription anticancer medicines, accurate product identification is particularly important because treatment decisions and safety monitoring depend on the correct medicine being supplied.

Product Quality and Pharmaceutical Standards

Medicines should be produced according to applicable pharmaceutical quality standards.

Manufacturing quality systems are designed to support consistent product identity, strength, purity and quality.

Relevant quality considerations may include:

  • Raw material control.
  • Manufacturing process validation.
  • Quality testing.
  • Contamination prevention.
  • Batch documentation.
  • Packaging controls.
  • Storage requirements.
  • Distribution controls.

Patients generally cannot establish manufacturing quality by examining a package alone. Appropriate documentation and authorized pharmaceutical supply channels are important.

Regulatory Authorization

Regulatory authorization is specific to the product and jurisdiction.

A medicine authorized in one country is not automatically authorized in every other country.

For Pemitinib, the relevant national regulatory status should be confirmed through official records and product documentation.

The authorization of PEMAZYRE should not be presented as proof that Pemitinib has an equivalent authorization.

Information Patients Should Check

Before using a Pemitinib product, patients and healthcare professionals should confirm:

  1. The product name.
  2. The active ingredient.
  3. The stated strength.
  4. The dosage form.
  5. The legal manufacturer.
  6. The batch or lot number.
  7. The expiry date.
  8. The product leaflet.
  9. The applicable regulatory information.
  10. The legitimacy of the supply channel.

Any inconsistency should be referred to an appropriate pharmaceutical professional or regulatory organization.

Conclusion

Pemigatinib is the active ingredient associated with Pemitinib 13.5 mg and the established reference product PEMAZYRE.

Incyte is associated with the development of pemigatinib and the reference product. This does not establish that Incyte manufactures Pemitinib.

The manufacturer of the specific Pemitinib product must be verified through its own packaging and official documentation. Accurate manufacturer identification supports transparency, pharmaceutical traceability and responsible medicine use.